Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.

Abstract

BACKGROUND/AIM:

Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma.

PATIENTS AND METHODS:

The medical records of 53 consecutive patients were reviewed and analyzed.

RESULTS:

Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006).

CONCLUSION:

Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.

• Authors: Kazuo Kobayashi, Yusuke Iikura, Makoto Hiraide, Takashi Yokokawa, Takeshi Aoyama, Sari Shikibu, Koki Hashimoto, Kenichi Suzuki, Hitoshi Sato, Erika Sugiyama, Masataka Tajima, Toshihiro Hama
• Journal: In vivo (Athens, Greece) (In Vivo) 2020 Sep-Oct Vol. 34 Issue 5 Pg. 2647-2652 ISSN: 1791-7549 [Electronic] Greece
• PMID: 32871795 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antineoplastic Agents, Immunological
• Nivolumab

Topics

• Antineoplastic Agents, Immunological (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Carcinoma, Renal Cell (drug therapy)
• Humans
• Kidney Neoplasms (drug therapy)
• Lung Neoplasms (drug therapy)
• Nivolumab (adverse effects)
• Retrospective Studies